Leerink Partnrs Has Bullish Forecast for RXRX Q3 Earnings

Key Points

• Investment analysts at Leerink Partners have raised their Q3 2025 earnings estimates for Recursion Pharmaceuticals (NASDAQ: RXRX) from ($0.32) to ($0.24) per share.
• The company's most recent quarterly earnings report revealed a loss of ($0.41) EPS, which missed the consensus estimate of ($0.35) by $0.06, despite revenue exceeding estimates.
• Recursion Pharmaceuticals has a consensus rating of "Hold" among analysts, with an average target price of $7.00, while 89.06% of its stock is owned by institutional investors.

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) - Leerink Partnrs boosted their Q3 2025 earnings per share estimates for Recursion Pharmaceuticals in a report issued on Tuesday, August 5th. Leerink Partnrs analyst M. Foroohar now expects that the company will post earnings of ($0.24) per share for the quarter, up from their prior forecast of ($0.32). The consensus estimate for Recursion Pharmaceuticals' current full-year earnings is ($1.57) per share. Leerink Partnrs also issued estimates for Recursion Pharmaceuticals' Q4 2025 earnings at ($0.14) EPS, FY2025 earnings at ($1.29) EPS, FY2026 earnings at ($0.81) EPS and FY2027 earnings at ($0.36) EPS.

A number of other analysts have also commented on the company. Morgan Stanley started coverage on Recursion Pharmaceuticals in a report on Thursday, July 3rd. They issued an "equal weight" rating and a $5.00 price target on the stock. Needham & Company LLC reiterated a "buy" rating and set a $8.00 target price on shares of Recursion Pharmaceuticals in a report on Tuesday, July 8th. Four investment analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Hold" and an average target price of $7.00.

Recursion Pharmaceuticals Stock Down 0.9%

Shares of Recursion Pharmaceuticals stock traded down $0.05 during trading on Friday, reaching $5.36. The stock had a trading volume of 11,988,952 shares, compared to its average volume of 29,196,614. The company has a market capitalization of $2.18 billion, a price-to-earnings ratio of -3.01 and a beta of 0.93. The stock has a fifty day moving average price of $5.40 and a two-hundred day moving average price of $5.89. Recursion Pharmaceuticals has a 52 week low of $3.79 and a 52 week high of $12.36. The company has a current ratio of 3.58, a quick ratio of 4.11 and a debt-to-equity ratio of 0.02.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last issued its quarterly earnings results on Tuesday, August 5th. The company reported ($0.41) EPS for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.06). The firm had revenue of $19.10 million during the quarter, compared to the consensus estimate of $15.38 million. Recursion Pharmaceuticals had a negative net margin of 1,004.91% and a negative return on equity of 76.09%. The business's revenue for the quarter was up 33.3% on a year-over-year basis. During the same quarter last year, the firm earned ($0.40) earnings per share.

Institutional Trading of Recursion Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the stock. Ensign Peak Advisors Inc increased its position in Recursion Pharmaceuticals by 0.3% during the fourth quarter. Ensign Peak Advisors Inc now owns 410,286 shares of the company's stock worth $2,774,000 after buying an additional 1,300 shares during the last quarter. Summit Investment Advisors Inc. increased its position in Recursion Pharmaceuticals by 7.8% during the fourth quarter. Summit Investment Advisors Inc. now owns 26,030 shares of the company's stock worth $176,000 after buying an additional 1,875 shares during the last quarter. Clear Creek Financial Management LLC increased its position in Recursion Pharmaceuticals by 9.8% during the first quarter. Clear Creek Financial Management LLC now owns 21,315 shares of the company's stock worth $113,000 after buying an additional 1,907 shares during the last quarter. GAMMA Investing LLC increased its position in Recursion Pharmaceuticals by 39.0% during the first quarter. GAMMA Investing LLC now owns 7,224 shares of the company's stock worth $38,000 after buying an additional 2,026 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. increased its position in Recursion Pharmaceuticals by 16.8% during the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 15,439 shares of the company's stock worth $78,000 after buying an additional 2,219 shares during the last quarter. Institutional investors own 89.06% of the company's stock.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.